Page 15 - FLIPBOOK
P. 15
Conclusions – docetaxel and disease burden in
STAMPEDE
• Docetaxel + ADT improves OS and FFS in newly diagnosed mHNPC regardless of
metastatic burden
• It should now be considered as a first-line option alongside AR targeting agents
for all de novo mHNPC patients regardless of stratification for “disease burden”
ADT, androgen deprivation therapy; AR, androgen receptor; FFS, failure-free survival; mHNPC, metastatic hormone-naïve prostate cancer; OS, overall survival.
Clarke NW, et al. Ann Oncol. 2019;30(12):1992–2003.
